Login to Your Account

Spectrum's Pivotal BELIEF: PTCL Data 'Topo' the Mark

By Randy Osborne
Staff Writer

Wednesday, December 26, 2012
Spectrum Pharmaceuticals Inc.'s endpoint-beating success in the pivotal Phase II study with belinostat for relapsed/refractory peripheral T-cell lymphoma (PTCL) keeps the firm on track potentially to pair the pan-histone deacetylase (HDAC) inhibitor with Spectrum's antifolate Folotyn (pralatrexate), already approved for the condition.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription